Caribou Biosciences (CRBU) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and technology platform

• Focus on allogeneic, off-the-shelf CAR T-cell therapies to expand access in oncology and autoimmune diseases.

• Next-generation CRISPR (Chardonnay) technology enables precise, multiplex genome editing for enhanced cell therapies.

• Four clinical programs are advancing, with multiple milestones and data readouts expected in 2025.

• Strong cash position of $281 million supports operations into the second half of 2026.

• Off-the-shelf approach addresses challenges of autologous therapies, including access, speed, and scalability.

Clinical pipeline and key programs

• CB-010 (anti-CD19) is in phase I for large B-cell lymphoma and lupus, with pivotal study decision expected by year-end.

• CB-011 (BCMA-targeted) for multiple myeloma, with at least 15-patient data readout planned in the first half of 2024.

• CB-012 (CLL-1 targeted) for AML, leveraging both PD-1 knockout and immune cloaking strategies, progressing through dose escalation.

• Manufacturing process enables over 300 doses per run, supporting large-scale patient access.

• RMAT designation for CB-010 facilitates ongoing FDA dialogue and regulatory advancement.

Clinical data and outcomes

• CB-010 shows durable complete remissions, with the first patient in CR for over three years after a single dose.

• HLA matching (≥4 alleles) between donor and patient correlates with outcomes on par with autologous CAR Ts.

• Safety profile of CB-010 is generally well-tolerated, with key adverse event rates comparable or better than auto CAR Ts.

• B-cell aplasia data in oncology supports rationale for use in lupus, with deep and sustained B-cell depletion.

• CB-011 incorporates immune cloaking to slow rejection and is benchmarked against bispecifics for efficacy and durability.